**Age-related macular degeneration (AMD)** is an eye disease that makes it hard to see clearly in the center of your vision. The middle part of the eye, called the macula, gets damaged as people get older. In **dry AMD**, this damage can lead to serious vision loss called **geographic atrophy**. Researchers are testing a new treatment, **ASP7317**, which uses special stem cells injected under the macula to try to fix the damage and improve vision.
The study will last up to one year. Participants will visit the clinic multiple times for check-ups and tests. In the study, participants will get one of three doses of ASP7317 and will also take the medicine tacrolimus to help their body accept the new cells.
- Study lasts one year with several clinic visits.
- Participants will receive an injection of ASP7317 and take medicine to prevent rejection.
- Researchers will monitor safety and vision improvement.
How understandable was the trial content above?
Hard to understand
Easy to understand